Ethyl 3,4-Dimethyl-5-Pyrrolecarboxylicacid

In the synthesis of non-steroidal anti-inflammatory drug (NSAID) active pharmaceutical ingredients (APIs), ethyl 3,4-dimethyl-5-pyrrolecarboxylate functions as the sole pyrrole-ring precursor in a convergent, three-stage manufacturing route that has been scaled to multi-hundred-kilogram batches under full ICH Q7 and FDA 21 CFR Part 211 cGMP compliance. The intermediate is registered under REACH (EC No. 218-598-2) and, when incorporated into a drug master file, must satisfy the residual solvent limits of USP <467> for dimethylformamide (class 2, <880 ppm) and ethyl acetate (class 3). The downstream chemistry exploits the nucleophilicity of the pyrrole nitrogen and the electrophilicity of the ester carbonyl in successive operations that directly fashion the pyrrolo[1,2-a]pyrrole skeleton characteristic of Ketorolac Tromethamine.

During the critical N-alkylation step, ethyl 3,4-dimethyl-5-pyrrolecarboxylate is charged at a molar ratio of 1.00–1.02 equivalents relative to the 2-bromoacetophenone acylating agent; exceeding 1.05 equivalents promotes quaternisation at the pyrrole nitrogen, generating a recalcitrant dimer that must be removed by hot filtration through a 0.5 µm sintered glass plate, reducing overall yield by up to 7%. The alkylation is conducted in anhydrous DMF at 80–85 °C for 6–8 h with finely milled anhydrous K₂CO₃ (325 mesh) as the acid scavenger, stirred at 250 rpm in a 5000 L glass-lined reactor equipped with a retreat-curve impeller and a nitrogen sweep to maintain headspace oxygen below 2 vol%. Subsequent Dieckmann-type cyclisation uses a freshly prepared sodium ethoxide solution (21 wt% in ethanol) added dropwise at 20–25 °C over 90 min; the reaction mass self-heats to 52 °C under controlled jacket cooling, and deviation beyond ±3 °C triggers premature precipitation of the β-ketoester intermediate, leading to a thick slurry that stalls the agitator drive motor if current draw exceeds 45 A on the 37 kW drive. After hydrolysis with 6 N HCl at reflux (103–105 °C), the liberated CO₂ generates foam heights of 1.2–1.8 m in an unbaffled vessel; mechanical foam breaker paddles rotating at 60 rpm and a slow heat ramp of 0.5 °C/min through the 70–90 °C window are mandatory to prevent material loss into the vapour line. The resulting crude ketorolac free acid is recrystallised from isopropanol/water (70:30 v/v) with charcoal treatment (2 wt% Norit SX Plus) to achieve single impurity levels below 0.10% by HPLC (λ = 313 nm, USP Ketorolac Tromethamine RS), then salified with tromethamine in aqueous ethanol to yield the injectable-grade API, which routinely meets the USP 43–NF 38 acceptance criteria for dissolution (NLT 85% in 30 min using Apparatus 2 at 50 rpm in 0.1 N HCl). The terminal dosage forms are aqueous injections (15 mg/mL and 30 mg/mL), ophthalmic solutions (0.5% w/v), and compressed tablets (10 mg), all manufactured on dedicated lines with confirmed freedom from cross-contamination as per 21 CFR 211.67 cleaning validation protocols.

Porphyrin-based photosensitizers approved for photodynamic therapy (PDT) of actinic keratosis and certain solid tumours derive their tetrapyrrole macrocycle from pyrrole building blocks, and ethyl 3,4-dimethyl-5-pyrrolecarboxylate is utilised specifically where 3,4-dimethyl substitution is required on the β-positions of the porphyrin periphery to modulate lipophilicity and tune the Q-band absorption profile. Before macrocyclisation, the ester is typically saponified to the free carboxylic acid under 2 N NaOH in methanol at 65 °C for 4 h to generate 3,4-dimethyl-5-pyrrolecarboxylic acid, which is then recrystallised from 50% aqueous ethanol (purity by anhydrous titration >99.0%). In the standard Adler-Longo condensation, the acid is dissolved in propionic acid (reagent grade, iron <5 ppm) in a 1000 L glass-lined reactor fitted with a packed reflux condenser, and benzaldehyde is added to achieve a pyrrole:aldehyde molar ratio of exactly 4.0:4.0, giving a pyrrole concentration of approximately 0.8 M. The dark purple mixture is heated to gentle reflux (141 °C) under a constant nitrogen flow and held for 45 min; extending the reflux beyond 60 min results in the formation of the chlorine analogue (through acid-catalysed oxidation) at levels exceeding 2.5 area% as measured by normal-phase HPLC (silica, hexane:THF 85:15). After cooling to 5 °C, the meso-tetraphenylporphyrin precipitate is collected on a 5 µm polypropylene cloth, washed with methanol until the effluent shows negligible absorbance at 410 nm, and dried under vacuum (50 °C, 20 mbar) to a loss on drying below 0.5%. The relevant regulatory framework intersects ICH Q3C (ethanol, propionic acid as class 3 solvents), ISO 10993-1:2018 biological evaluation for the finished sensitizer formulation, and the European Pharmacopoeia monograph for porfimer sodium, which sets a limit of NMT 1.5% for high-molecular-weight oligomers. The ester is thus consumed at a stoichiometric loading of 4.0 mol per mol of porphyrin product during macrocycle construction. The terminal products include hematoporphyrin derivative (HpD), temoporfin (m-THPC), and various ester-linked photosensitizer precursors that are formulated as lyophilised powders for reconstitution into sterile intravenous solutions typically containing 15 mg of active porphyrin per vial, administered prior to laser irradiation at 652 nm or 514 nm.

GABA-gated Chloride Channel Modulator Insecticides – Pyrrole Intermediates Compliant with FAO Specification 581/TC

Ethyl 3,4-dimethyl-5-pyrrolecarboxylate finds application as a flexible synthon in the assembly of arylpyrrole acaricides and insecticides that act as pro-insecticides requiring oxidative bioactivation in the target organism. Within this category, FAO Specification 581/TC (Chlorfenapyr Technical) and EPA 40 CFR Part 180 tolerance guidelines establish the purity benchmarks that the downstream active ingredient must achieve, but the pyrrole intermediate itself is handled under internal quality agreements referencing CIPAC Handbook K methods for identity and assay. In a typical route to 2-aryl-5-(trifluoromethyl)pyrrole-3-carbonitrile core structures, the ethyl 3,4-dimethyl-5-pyrrolecarboxylate is employed as the pyrrole ring donor in a Meervein arylation sequence: it is first N-protected with trifluoroacetyl (TFAA, 2.5 eq in CH₂Cl₂ at 0 °C) to prevent N-arylation side products, then subjected to a palladium-catalysed decarboxylative cross-coupling with 2-bromo-4-chloro-1-(trifluoromethyl)benzene. The reaction employs 10 mol% Pd(PPh₃)₄, 1.2 eq of CuTC, and is run in N-methyl-2-pyrrolidone at 120 °C for 18 h in a 316L stainless-steel autoclave rated to 20 bar. The ethyl ester loading is set at 1.05–1.10 molar equivalents relative to the aryl bromide; lower ratios leave unreacted aryl halide that co-elutes during silica chromatography (hexane:ethyl acetate 9:1), while higher ratios promote homocoupling giving a dimethylene-bridged byproduct detectable at Rf 0.45 (versus Rf 0.31 for the target intermediate). After protective group removal with aqueous ammonia in methanol (7 N, 50 °C, 3 h), the free pyrrole is chemically chlorinated with sulfuryl chloride (1.02 eq) in anhydrous ether at −10 °C to install the 4-chloro substituent demanded by the pharmacophore. This controlled low-temperature step is critical because a temperature excursion to +5 °C initiates di-chlorination, increasing the proportion of the 4,5-dichloro impurity to >8 area%, at which point the batch falls outside the downstream FTO alkylation selectivity window. Subsequent condensation with ethyl cyanoacetate under basic conditions (piperidine, acetic acid, toluene, Dean-Stark azeotropic removal) yields the requisite 2-aryl-3-carbonitrile intermediate, which is then reduced and cyclised to the final active substance. The terminal product, Chlorfenapyr technical (assay ≥94% as per FAO 581/TC), is formulated as a suspension concentrate (240 g/L SC) and applied at field rates between 75 and 150 g a.i./ha. Throughout the synthesis, the use of ethyl 3,4-dimethyl-5-pyrrolecarboxylate is confined to a dedicated production building with HEPA-filtered drying suites to comply with the <1 µg/m³ airborne exposure limit recommended for susceptible heterocyclic intermediates under ECHA occupational exposure band E.

Targeted covalent inhibitors engaging a non-catalytic cysteine in the kinase hinge region frequently incorporate a 3,4-dimethylpyrrole fragment to achieve shape complementarity with the hydrophobic back pocket of the ATP-binding site, and ethyl 3,4-dimethyl-5-pyrrolecarboxylate serves as a direct entry point to these elaborated heterocycles through successive C–H functionalisation and palladium-mediated cross-coupling. The development-stage synthetic route adopted for a dual AcK1/FLT3 inhibitor (Phase II clinical candidate) commences with regioselective bromination of the pyrrole C2 position using N-bromosuccinimide (1.05 eq) in THF at 0–5 °C, which proceeds with >20:1 selectivity over the C5 position when the ester is present as the ethyl ester; the methyl ester analogue shows diminished selectivity (~8:1) due to differences in the steric environment around the carbonyl oxygen as assessed by DFT calculations at the B3LYP/6-311+G(d) level. The resulting bromopyrrole ester is then converted to the corresponding pinacol boronate using bis(pinacolato)diboron (1.2 eq), KOAc (3.0 eq), and 0.5 mol% Pd(dppf)Cl₂·CH₂Cl₂ in 1,4-dioxane at 85 °C under an argon atmosphere, achieving complete conversion within 3 h as monitored by LCMS (m/z 324 [M+H]⁺). The loading of the pyrrole building block in the subsequent Suzuki–Miyaura coupling is fixed at 1.0:1.15 (boronate:heteroaryl bromide) to drive full consumption of the expensive difluoromethoxy-substituted quinazoline electrophile, while the use of K₃PO₄ (1.5 M aqueous) in a 5:1 toluene/ethanol mixture at 78 °C maintains the palladium in the active Pd⁰ state without inducing protodeborylation. The work-up involves filtration through a 0.2 µm PTFE membrane to remove palladium residues (target <10 ppm Pd in the isolated solid, consistent with the ICH Q3D parenteral concentration limit), followed by trituration with n-heptane to remove residual pinacol. A single recrystallisation from acetonitrile yields the advanced intermediate in 89–91% isolated yield with a chemical purity of 99.3% by HPLC area (λ = 254 nm). The subsequent amide coupling with a side-chain amino alcohol uses HATU (1.1 eq) and DIPEA (2.5 eq) in DMF at 0 °C, providing the active pharmaceutical ingredient candidate after chiral SFC separation (Chiralpak IC, 25:75 methanol/CO₂, 40 °C, 100 bar). All process steps are conducted under ICH M7 purge factor calculations for mutagenic impurities, and the final compound is tested against the EMA guideline on process validation (CPMP/QWP/848/96) for commercial readiness. The terminal dosage form under investigation is a hard gelatin capsule containing 25 mg and 100 mg of the micronised free base blended with lactose monohydrate and croscarmellose sodium, intended for once-daily oral administration.